MMHA 6400 Week 5: sample paper, in real form

Financial Analysis of a Hospital-Based Outpatient Infusion Center: Payer Mix, a $435.00 Contribution Margin per Visit, and the Case for Two More Chairs

Student Name

Master of Healthcare Administration Program, Walden University

MMHA 6400: Healthcare Finance

Instructor Name

Month Day, Year

The Service Line, the Decision, and the Figures Behind Every Number

Cedar Ridge Regional Health is a composite 240-bed nonprofit community hospital used here to carry the method; no real organization's books are reproduced, and every figure below is illustrative. Its hospital-based outpatient infusion center runs six chairs, ten hours a day, 250 days a year, which is 15,000 available chair-hours. In fiscal 2025 the center completed 5,100 visits at an average of 2.5 chair-hours each, using 12,750 hours, or 85.0 percent of capacity. Scheduling now defers roughly 640 visits a year beyond fourteen days or sends them out of the system. The finance committee asked whether to add two chairs and one nursing position, which is a question about incremental dollars rather than about whether the service line as a whole is profitable.

Every number in this analysis comes from the figures printed here. Payer mix by visit was Medicare 46.0 percent, or 2,346 visits, at net revenue of $1,180.00 per visit; commercial 34.0 percent, or 1,734 visits, at $2,240.00; Medicaid 14.0 percent, or 714 visits, at $780.00; and self-pay and other 6.0 percent, or 306 visits, at $190.00 after charity care and bad debt. Those four lines total $7,267,500 of net patient service revenue and a blended $1,425.00 per visit. The spread across payers is wide because hospital outpatient payment for an infusion pairs a drug payment with a separately payable administration service, and the two are priced very differently from one payer to the next (Centers for Medicare & Medicaid Services, 2024).

Cost is reported in three layers because each layer answers a different question. Variable cost is $990.00 per visit: $952.00 of drug acquisition and $38.00 of supplies and pharmacy consumables. Direct fixed cost is $1,200,000, made up of $808,000 of labor, being 5.0 registered nurse positions at $104,000 loaded, one pharmacy technician, a half-time pharmacist, 1.5 scheduling and registration positions, and 0.4 of a nurse manager, plus $392,000 of space, equipment depreciation, purchased services, and malpractice. Hospital overhead allocated to the line is $612,000. Contribution margin tests the next visit, direct margin tests what the manager controls, and fully allocated margin tests the service line's claim on the hospital (Reiter & Song, 2021).

Contribution Margin by Payer, and Why the Blended Figure Misleads

Blended contribution margin is $1,425.00 of net revenue less $990.00 of variable cost, or $435.00 per visit, and 5,100 visits produce $2,218,500. Subtracting $1,200,000 of direct fixed cost leaves a direct margin of $1,018,500, which is 14.0 percent of net revenue. Subtracting the $612,000 overhead allocation leaves a fully allocated margin of $406,500, or 5.6 percent. On those three figures alone the service line looks healthy and the recommendation writes itself, which is exactly the trap. A blended margin is the average of four businesses that behave nothing alike, and this average is held up almost entirely by one of them.

Computed per payer, contribution margin per visit is $190.00 for Medicare, $1,250.00 for commercial, negative $210.00 for Medicaid, and negative $800.00 for self-pay and other. Multiplied by the volumes, Medicare contributes $445,740, commercial contributes $2,167,500, Medicaid consumes $149,940, and self-pay consumes $244,800. The four figures sum to $2,218,500, the same total the blended calculation produced, and that reconciliation matters. It shows the mix view and the blended view are one analysis rather than two, so a reader can check either against the other without leaving the page.

The finding follows from the arithmetic. Commercial visits are 34.0 percent of the volume and 97.7 percent of the contribution. Medicare is 46.0 percent of the volume and 20.1 percent of the contribution, and the two remaining categories together remove $394,740 before a single fixed cost is paid. Contribution economics of this shape are ordinary in drug-heavy outpatient services, where acquisition cost sits close to the payment rate for the lowest-paying categories (Cleverley et al., 2018). The management consequence is specific. Adding visits raises margin only if the added visits carry the payer mix the current margin depends on, and a referral count says nothing about whether they do.

Break-Even, Margin of Safety, and the Incremental Case for Two Chairs

Two break-even points belong in this paper because they answer different questions. Against direct fixed cost alone, the center covers what its manager controls at $1,200,000 divided by $435.00, or 2,759 visits. Against direct fixed cost plus the overhead allocation, it covers its claim on the hospital at $1,812,000 divided by $435.00, or 4,166 visits. Actual volume of 5,100 sits 934 visits above the higher of the two, a margin of safety of 18.3 percent. That cushion belongs to the mix and not to the volume: a ten point shift of visits from commercial to Medicare would cut blended contribution margin to $329.00 and lift the fully allocated break-even to 5,508 visits, which is more than the center does today.

The expansion adds two chairs, or 5,000 chair-hours, which at 2.5 hours per visit lifts capacity from 6,000 to 8,000 visits a year. Year-one incremental volume is taken as the 640 visits the referral log already shows, and that volume is modeled at its own mix rather than the center's, because deferred referrals skew toward Medicare: 352 Medicare visits, 160 commercial, 96 Medicaid, and 32 self-pay. Priced at the same rates, incremental net revenue is $854,720, a blended $1,335.50 per visit, so incremental contribution margin is $345.50 per visit and incremental contribution is $221,120.

Incremental fixed cost is $164,800: $104,000 for one registered nurse position, $34,000 for a half-time pharmacy technician, $11,600 of depreciation on $58,000 of chairs and pumps over five years, $9,200 on a $92,000 build-out of the adjacent room over ten years, and $6,000 of software and other recurring cost. Incremental direct margin is therefore $56,320, or 6.6 percent of incremental net revenue. Break-even on the expansion is $164,800 divided by $345.50, or 477 visits, which means 74.5 percent of the deferred referrals have to arrive before the two added chairs pay for themselves. Against $150,000 of capital and $77,120 of incremental cash margin before depreciation, simple payback is about 1.9 years.

Sensitivity, Recommendation, and the Measures That Will Test It

The result is fragile in one direction only. Commercial payers in this market are steering infusions toward freestanding and home settings, and the payment differential between hospital outpatient departments and other sites of care has been examined at length in Medicare payment policy (Medicare Payment Advisory Commission, 2024). The sensitivity worth running is therefore a lower commercial share of the incremental volume. At 15 percent commercial rather than 25 percent, the 640 visits become 416 Medicare, 96 commercial, 96 Medicaid, and 32 self-pay. Incremental net revenue falls to $786,880, contribution margin falls to $239.50 per visit, and incremental contribution of $153,280 no longer covers $164,800 of added fixed cost, producing a first-year loss of $11,520 and a break-even of 688 visits, more than the referral log contains. The expansion is not a volume decision, it is a mix decision, and the referral log alone cannot tell the committee which one it has.

One lever is larger than the entire expansion and needs no capital. Drug acquisition is $4,855,200 of the $5,049,000 in variable cost, or 96.2 percent of it, so a 3.0 percent reduction in acquisition cost per visit, from $952.00 to $923.44, releases $145,656 a year at current volume. That is 2.6 times the $56,320 the two chairs are expected to earn, and it arrives without a new position, a build-out, or a chair. Biosimilar substitution on the two highest-volume reference products is the realistic route, since an approved biosimilar carries no clinically meaningful difference from the product it references and generally enters at a lower price (U.S. Food and Drug Administration, 2024).

Three recommendations follow, each with a trigger and a measure. First, approve the $92,000 build-out and the two chairs now but hold the nursing position until the referral log shows 40 scheduled incremental visits a month for two consecutive months, since 480 visits a year clears the 477 break-even. Second, report the commercial share of incremental volume monthly against a floor of 20 percent, because the expansion breaks even at a 16.7 percent commercial share and a floor set at the break-even leaves nothing to react with. Third, take the pharmacy action whatever the committee decides about chairs, measured as drug cost per visit against a $923.44 target and reported on the same monthly cycle as the department's other performance measures (Healthcare Financial Management Association, 2024). The service line is sound. The expansion is a $56,320 bet on holding one payer class, and it should be sized, staged, and watched like one.

References

Centers for Medicare & Medicaid Services. (2024). Hospital outpatient prospective payment system. U.S. Department of Health and Human Services. https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient

Cleverley, W. O., Cleverley, J. O., & Song, P. H. (2018). Essentials of health care finance (8th ed.). Jones & Bartlett Learning.

Healthcare Financial Management Association. (2024). MAP keys: Industry-standard revenue cycle performance metrics. Healthcare Financial Management Association. https://www.hfma.org/

Medicare Payment Advisory Commission. (2024). Report to the Congress: Medicare payment policy. Medicare Payment Advisory Commission. https://www.medpac.gov/

Reiter, K. L., & Song, P. H. (2021). Gapenski's healthcare finance: An introduction to accounting and financial management (8th ed.). Health Administration Press.

U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biological products. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/biosimilars